2m 2m 2m 2m 2m 2m 2m
Halozyme Therape (HALO)
NASDAQ
$108.34+$0.17 (+0.16%)
Price as of Aug 21, 2026 7:42 PM EDT- $12.3BMarket Cap
- 50.61%1-Year Change
- BiotechnologyIndustry
Halozyme Therape (HALO)
$108.34+$0.17 (+0.16%)
HALO | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $108.17 | ||
Change | +$2.05 (+1.93%) | ||
Open | $106.20 | ||
High | $108.49 | ||
Low | $105.91 | ||
Previous Close | $106.12 | ||
Volume | 1,174,232 | ||
30-Day Average Volume | 2,326,320 | ||
1-Week Change | 9.64% | ||
1-Month Change | 37.62% | ||
1-Year Change | 50.61% | ||
3-Year Change | 153.80% | ||
5-Year Change | 173.50% | ||
Fundamentals | |||
Shares Outstanding | 113.5M | ||
Total Assets | $2.6B | ||
Market Cap | $12.3B | ||
Enterprise Value | $14.3B | ||
Period: QTR TTM FY | |||
Revenue | $307.7M | ||
Net Income | $229.9M | ||
Free Cash Flow | $236.7M | ||
EBIT | $285.3M | ||
EBITDA | $314.8M | ||
Net Working Capital | $588.6M | ||
EPS | $1.90 | ||
Enterprise Value/EBITDA | 45 | ||
Enterprise Value/Revenue | 46 | ||
P/B | 86 | ||
P/E | 57 | ||
PEG | 1 | ||
Price/Free Cash Flow | 52 | ||
Price/Operating Cash Flow | 51 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue